. "Efficacy and safety of certolizumab pegol in the treatment of rheumatoid arthritis"@en . . . "3" . "RIV/00216208:11110/11:10222" . . "1"^^ . "certolizumab pegol; rheumatoid arthritis; TNF-alpha inhibitors"@en . "CZ - \u010Cesk\u00E1 republika" . "Efficacy and safety of certolizumab pegol in the treatment of rheumatoid arthritis"@en . "7" . "1"^^ . . "Certolizumab pegol je nov\u00FD inhibitor TNF-alfa, jeho\u017E molekula je slo\u017Eena z fragment\u016F monoklon\u00E1ln\u00ED protil\u00E1tky, spojen\u00FDch pegolem. Je indikov\u00E1n v l\u00E9\u010Db\u011B aktivn\u00ED revmatoidn\u00ED artritidy po selh\u00E1n\u00ED terapie chorobu modifikuj\u00EDc\u00EDmi l\u00E9ky RA (DMARDs), pod\u00E1v\u00E1 se v subkut\u00E1nn\u00ED injekci v d\u00E1vce 400mg v t\u00FDdnech 0, 2 a 4, pot\u00E9 se pokra\u010Duje d\u00E1vkou 200mg jednou za dva t\u00FDdny. Kombinace s metotrex\u00E1tem je \u00FA\u010Dinn\u011Bj\u0161\u00ED, lze jej v\u0161ak u\u017E\u00EDt i v monoterapii. Ne\u017E\u00E1douc\u00ED \u00FA\u010Dinky jsou obdobn\u00E9 jako u ostatn\u00EDch inhibitor\u016F TNF, klinicky nejz\u00E1va\u017En\u011Bj\u0161\u00ED jsou infekce v\u010Detn\u011B aktivace latentn\u00ED tuberkul\u00F3zy."@cs . "Olej\u00E1rov\u00E1, Marta" . "Farmakoterapie" . . . . "Bezpe\u010Dnost a \u00FA\u010Dinnost certolizumab pegolu v l\u00E9\u010Db\u011B revmatoidn\u00ED artritidy" . . "11110" . "Certolizumab pegol je nov\u00FD inhibitor TNF-alfa, jeho\u017E molekula je slo\u017Eena z fragment\u016F monoklon\u00E1ln\u00ED protil\u00E1tky, spojen\u00FDch pegolem. Je indikov\u00E1n v l\u00E9\u010Db\u011B aktivn\u00ED revmatoidn\u00ED artritidy po selh\u00E1n\u00ED terapie chorobu modifikuj\u00EDc\u00EDmi l\u00E9ky RA (DMARDs), pod\u00E1v\u00E1 se v subkut\u00E1nn\u00ED injekci v d\u00E1vce 400mg v t\u00FDdnech 0, 2 a 4, pot\u00E9 se pokra\u010Duje d\u00E1vkou 200mg jednou za dva t\u00FDdny. Kombinace s metotrex\u00E1tem je \u00FA\u010Dinn\u011Bj\u0161\u00ED, lze jej v\u0161ak u\u017E\u00EDt i v monoterapii. Ne\u017E\u00E1douc\u00ED \u00FA\u010Dinky jsou obdobn\u00E9 jako u ostatn\u00EDch inhibitor\u016F TNF, klinicky nejz\u00E1va\u017En\u011Bj\u0161\u00ED jsou infekce v\u010Detn\u011B aktivace latentn\u00ED tuberkul\u00F3zy." . "http://www.farmakoterapie.cz/farmakoterapie-archiv-cisel?id=3545" . . "Bezpe\u010Dnost a \u00FA\u010Dinnost certolizumab pegolu v l\u00E9\u010Db\u011B revmatoidn\u00ED artritidy"@cs . . . "188115" . . "V" . "RIV/00216208:11110/11:10222!RIV12-MSM-11110___" . "[C62B9F998E0F]" . "Bezpe\u010Dnost a \u00FA\u010Dinnost certolizumab pegolu v l\u00E9\u010Db\u011B revmatoidn\u00ED artritidy" . . "Bezpe\u010Dnost a \u00FA\u010Dinnost certolizumab pegolu v l\u00E9\u010Db\u011B revmatoidn\u00ED artritidy"@cs . "7"^^ . . "1801-1209" . "Certolizumab pegol is a new TNF- inhibitor consisting of two fragments of monoclonal antibody, connected with pegol. It is indicated in active rheumatoid arthritis when the treatment with disease modifying drugs (DMARDs) failed. Certolizumab is given in subcutenous infections with 400mg of the drug in weeks 0, 2 a 4, then the treatment continues with the dose 200mg given once in two weeks. Combination with methotrexate is more effective, but certolizumab can be used also in monotherapy. Side effects are similar to other TNF-inhibitors, the most clinically significant adverse events are infections including activation of latent tuberculosis."@en .